Immunization and Vaccination: Types, Safety, Global Programs, Challenges, and Future Advances

Immunization is the process of making a person immune or resistant to an infectious disease, usually through vaccination (Adumashi et al., 2026; Kiboneka, 2021).
It works by stimulating the body’s natural immune system to recognize and fight harmful microorganisms (Introduction, History, Types of Vaccines, and Physiology of Immunization, 2024).
Vaccination and immunization are related but different terms:

Vaccination means giving a vaccine.
Immunization refers to the protection that develops after vaccination (Introduction, History, Types of Vaccines, and Physiology of Immunization, 2024; Kiboneka, 2021).

Vaccines may contain weakened germs, killed germs, or parts of germs called antigens.
These components safely train the immune system to recognize and fight infections later without causing the disease itself (Adumashi et al., 2026; Canouï & Launay, 2019).

Importance of Immunization in Public Health

Immunization is considered one of the greatest achievements in public health.
It protects both individuals and communities from infectious diseases.
Immunization saves millions of lives each year by preventing serious illnesses and reducing deaths (Montero et al., 2024; Piot et al., 2019).
Childhood vaccination has greatly reduced infant and child mortality worldwide (Pollard & Bijker, 2020; Shattock et al., 2024).
High vaccination coverage creates herd immunity, which protects people who cannot receive vaccines, such as newborns and immunocompromised individuals (Piot et al., 2019; Nuwarda et al., 2022).
Immunization also provides economic and social benefits by reducing healthcare expenses, improving school attendance, and increasing productivity (Hussain, 2019; De Los Santos et al., 2022).

Historical Background of Immunization

The history of immunization dates back several centuries and reflects continuous medical progress.
One of the earliest disease-prevention methods was variolation, practiced during the 17th century in China and other regions (Montero et al., 2024; Nuwarda et al., 2022).
Variolation involved deliberate exposure to material from smallpox lesions to provide protection against severe disease.
A major breakthrough occurred in 1796, when Edward Jenner discovered that cowpox infection could protect against smallpox (Hussain, 2019; De Los Santos et al., 2022).
Jenner’s findings led to the development of the first smallpox vaccine and marked the beginning of modern vaccination.
During the 19th and 20th centuries, vaccination programs expanded to diseases such as diphtheria, tetanus, pertussis, polio, and measles, greatly reducing illness and death worldwide (Pollard & Bijker, 2020; Conis, 2019).
One of the greatest successes of immunization was the global eradication of smallpox, officially declared in 1979 after worldwide vaccination campaigns (Piot et al., 2019; De Los Santos et al., 2022).
In 1974, the World Health Organization (WHO) launched the Expanded Programme on Immunization (EPI) to improve vaccine coverage globally.
The EPI has prevented millions of deaths and significantly improved child survival worldwide (Shattock et al., 2024; Cruz et al., 2025).
Modern vaccine technologies now include conjugate, recombinant, and mRNA vaccines.
Despite major achievements, challenges such as vaccine hesitancy, misinformation, and unequal vaccine access continue to affect immunization programs worldwide (Carvalho & De Oliveira Magalhães Júnior, 2025).

Understanding the Immune System

The immune system is the body’s defense system that protects against disease-causing organisms.
It helps fight:

Bacteria.
Viruses.
Fungi.
Parasites.
Toxins.

It works continuously to maintain body health and balance (Marshall et al., 2018; Ghosh et al., 2021).
A weak immune system leads to frequent infections, while an overactive one can cause allergies or autoimmune diseases (Rankin & Artis, 2018; Marshall et al., 2024).

Overview of the Immune System

The immune system is made up of cells, organs, and signaling molecules.
Main components include:

White blood cells (leukocytes).
Antibodies.
Cytokines.
Complement proteins (Parkin & Cohen, 2001; Marshall et al., 2018).

It protects the body by:

Preventing entry of pathogens.
Detecting harmful organisms inside the body.
Eliminating infections.

It also develops immune memory for faster protection in future infections (Warrington et al., 2011; Marshall et al., 2024).

Innate Immunity vs Adaptive Immunity

The immune system has two main defense systems:

Innate immunity

Acts quickly (minutes to hours).
Provides general, non-specific protection.
First line of defense.
Uses macrophages, neutrophils, dendritic cells, and NK cells.
Causes inflammation and phagocytosis (Marshall et al., 2018; Ghosh et al., 2021).
No memory response (Medzhitov & Janeway, 1997; Smith et al., 2019).

Adaptive immunity

Slower response (days).
Highly specific to pathogens.
Uses B cells and T cells.
Produces antibodies to neutralize infections (Kiboneka, 2021; Ghosh et al., 2021).
Develops immune memory for long-term protection (Marshall et al., 2024; Warrington et al., 2011).

Both systems work together for effective immune protection (Sun et al., 2020; Wang et al., 2024).

Role of Antibodies and Immune Cells

B cells

Produce antibodies that target specific pathogens.
Help in long-term immune protection (Liu et al., 2025; Ghosh et al., 2021).

Antibodies

Bind to pathogens.
Neutralize toxins and viruses.
Mark microbes for destruction.

T cells

Helper T cells activate immune responses.
Cytotoxic T cells destroy infected or abnormal cells (Pishesha et al., 2022).

Innate immune cells

Detect pathogens early.
Perform phagocytosis.
Present antigens to T cells.
Link innate and adaptive immunity (Sun et al., 2020; Marshall et al., 2024).

What is Immunization?

Immunization is a process that protects a person from infectious diseases by helping the body build immunity before infection occurs.
It is usually achieved through vaccination, where a safe form of a pathogen is introduced into the body.
The main purpose is to prepare the immune system so it can respond quickly and effectively when exposed to the real disease.
Immunization is one of the most important methods used in modern public health to prevent infectious diseases (Kiboneka, 2021; Khebade et al., 2024; Bulut, 2023; Pathan et al., 2025).

Definition and Concept

Immunization is the process of making a person immune or resistant to a specific infectious disease, mainly through vaccines (Kiboneka, 2021; Khebade et al., 2024; Touray & Touray, 2021; Bulut, 2023; Pathan et al., 2025).
Vaccination means giving a vaccine, while immunization refers to the protection that develops in the body after vaccination (Khebade et al., 2024; Touray & Touray, 2021; Pathan et al., 2025).
A vaccine is a biological substance made from:

Killed microorganisms.
Weakened microorganisms.
Parts of microorganisms (antigens).

These vaccine components stimulate the immune system without causing disease (Kennedy, 2020; Barman et al., 2022; Kiboneka, 2021).
Immunization also plays a major role in public health by protecting individuals and reducing disease spread in communities (John, 2018; Bulut, 2023).

How Immunization Works

A vaccine is given through different routes such as injection, oral, or nasal delivery.
The vaccine introduces harmless antigens into the body.
The immune system recognizes these antigens as foreign and activates immune defenses (Kiboneka, 2021; Bulut, 2023; Kennedy, 2020).
First, the innate immune system responds:

Detects the antigen.
Activates inflammation.
Engages immune cells like macrophages and dendritic cells (Rosenbaum et al., 2020; Pradeu et al., 2024).

Then, the adaptive immune system is activated:

B cells produce antibodies.
T cells help coordinate and destroy infected cells (Pulendran & Ahmed, 2006; Barman et al., 2022).

The immune system then creates a stronger and faster response for future protection.

Immunity Development Process

Step 1: Vaccine introduces antigen into the body, which is detected by immune cells (Kiboneka, 2021; Rosenbaum et al., 2020).
Step 2: Innate immune cells like macrophages and dendritic cells process the antigen and activate immune signaling (Pulendran & Ahmed, 2006; Pradeu et al., 2024).
Step 3: Adaptive immunity is activated:

B cells produce specific antibodies.
T cells coordinate and kill infected cells (Kennedy, 2020; Barman et al., 2022).

Step 4: Memory cells are formed:

Memory B cells and memory T cells remain in the body for long-term protection (Geckin et al., 2022; Vuscan et al., 2024).

Step 5: On real infection, the immune system responds faster and prevents or reduces disease severity (Rosenbaum et al., 2020; Bulut, 2023).

Types of Immunization

Immunization is mainly of two types:

Active immunization.
Passive immunization.

Each type can occur in:

Natural form.
Artificial form.

In active immunity, the body produces its own immune response.
In passive immunity, the body is given ready-made antibodies for immediate protection (Clem, 2011; Moore, 2019; Martin & Graham, 2016; Marcotte & Hammarström, 2015; Domachowske, 2020).

Active Immunization

Active immunization happens when the body is exposed to an antigen and produces its own immune response.
It provides long-lasting protection and often includes immune memory (Domachowske, 2020; Clem, 2011; Martin & Graham, 2016).
Protection develops slowly, usually over days to weeks, and may need booster doses.

Natural active immunization.

Occurs after a natural infection in daily life.
The immune system responds after the person gets infected.
Example: recovering from i.nfluenza and gaining immunity to that strain (Clem, 2011; Moore, 2019)

Artificial active immunization.

Occurs through vaccination.
Vaccines contain weakened, killed, or parts of germs that trigger immunity without causing disease (Baxter, 2007; Clem, 2011; Domachowske, 2020).
Used in routine childhood and adult immunization programs.

Passive Immunization

Passive immunization involves giving the body ready-made antibodies for immediate protection.
It works quickly but provides short-term protection (weeks to a few months) (Marcotte & Hammarström, 2015; Domachowske, 2020).
It does not usually create immune memory.

Natural passive immunization

Occurs when antibodies are transferred from mother to baby.
Happens through the placenta and breast milk.
Protects newborns in early life (Clem, 2011; Marcotte & Hammarström, 2015; Moore, 2019).

Artificial passive immunization

Involves giving prepared antibodies or immune products.
Examples include:

Immunoglobulin injections.
Antivenom.
Convalescent plasma.
Monoclonal antibodies (Sevilla, 2023; Moirangthem & Bar-On, 2025).

Vaccines and Their Role in Immunization

Vaccines are the main tools used in immunization to protect the body from infectious diseases.
They work by safely exposing the immune system to parts of germs so it can learn to fight real infections later.
Vaccination is the act of giving a vaccine, while immunization is the protection that develops in the body after vaccination (Marineci & Chiriţă, 2018; Lakshmanan & Karunakaran, 2020; Kiboneka, 2021).

Definition of Vaccines

A vaccine is a biological preparation that helps the body develop immunity against specific diseases (Pollard & Bijker, 2020; Clem, 2011).
It usually contains:

Killed microorganisms.
Weakened (attenuated) microorganisms.
Parts of microorganisms (antigens).
In some cases, toxins or genetic material.

The main purpose is to trigger protection without causing the actual disease (Touray & Touray, 2021; Vetter et al., 2018; Khebade et al., 2024).
Types of vaccines include:

Live attenuated vaccines.
Inactivated vaccines.
Subunit or fragment vaccines.
Toxoid vaccines.
Conjugate vaccines.
mRNA and other modern vaccine platforms (Chuah & Parasuraman, 2025; Vetter et al., 2018).

How Vaccines Stimulate Immunity

Vaccines introduce harmless antigens that resemble disease-causing organisms.
The immune system recognizes them as foreign and activates defense mechanisms (Calle, 2020; Pollard & Bijker, 2020).
First, the innate immune system responds:

Detects vaccine antigens.
Activates inflammation.

Engages immune cells like macrophages and dendritic cells.
Then, the adaptive immune system is activated:

B cells produce antibodies.
T cells help coordinate immune responses and kill infected cells (Clem, 2011; Vetter et al., 2018).

The immune system creates memory cells that remain in the body.
On later exposure to the real pathogen:

The response is faster and stronger.
Disease is prevented or becomes much milder (Pollard & Bijker, 2020; Kiboneka, 2021).

Difference Between Immunization and Vaccination

Vaccination

The process of giving a vaccine (injection, oral drops, etc.).
It is a medical procedure (Marineci & Chiriţă, 2018; Kiboneka, 2021).

Immunization

The result and process of developing immunity in the body.
It can occur after vaccination or natural exposure (Touray & Touray, 2021; Clem, 2011).

Key idea:

Vaccination = action (giving vaccine).
Immunization = outcome (protection developed) (Lakshmanan & Karunakaran, 2020).

Types of Vaccines

Vaccines are classified based on what they contain and how they stimulate the immune system.
Main categories include whole-organism vaccines, component vaccines, and genetic platform vaccines (Ghattas et al., 2021; Dai et al., 2019; Sáfadi, 2021).

Live Attenuated Vaccines

Contain live but weakened microorganisms that can still replicate but do not usually cause disease in healthy individuals.
They closely mimic natural infection and stimulate a strong immune response.
Often provide long-lasting immunity, sometimes after one or few doses.
Not recommended for immunocompromised individuals due to small risk of reactivation (Gupta & Pellett, 2023; Francis, 2017; Cid & Bolívar, 2021; Sáfadi, 2021; Motamedi et al., 2021).

Inactivated (Killed) Vaccines

Made from pathogens that are killed using heat, chemicals, or radiation.
Cannot replicate or cause disease.
Safer than live vaccines and suitable for most populations.
Usually require booster doses because immune response is weaker compared to live vaccines (Ghattas et al., 2021; Francis, 2017; Li et al., 2021; Bayani et al., 2023).

Toxoid Vaccines

Contain inactivated bacterial toxins (toxoids) instead of whole bacteria.
Protect against diseases caused by toxins rather than the bacteria itself.
Common examples include protection against toxin-mediated diseases.
Often require booster doses for long-term immunity (Cid & Bolívar, 2021; Gupta & Pellett, 2023).

Subunit Vaccines

Contain only specific parts of the pathogen such as proteins or polysaccharides.
Do not include the whole organism.
Safer because they cannot cause infection.
May require adjuvants and multiple doses to strengthen immunity (Ghattas et al., 2021; Francis, 2017; Li et al., 2021).

Recombinant Vaccines

A type of subunit vaccine produced using genetic engineering techniques.
Specific genes of a pathogen are inserted into expression systems to produce antigen proteins.
Allows large-scale and precise production of vaccine components.
Highly safe and widely used in modern vaccine development (Ghattas et al., 2021; Cid & Bolívar, 2021).

Conjugate Vaccines

Made by linking polysaccharide antigens to a protein carrier (often toxoid proteins).
This improves immune recognition, especially in infants and young children.
Enhances antibody response against bacterial capsule polysaccharides (Cid & Bolívar, 2021).

mRNA Vaccines

Contain messenger RNA (mRNA) that instructs body cells to produce a specific viral protein.
The immune system then recognizes this protein and builds immunity.
Do not contain live virus and cannot cause infection.
Rapid to design and produce, widely used in recent pandemic responses.
Require cold storage conditions in many cases (Ghattas et al., 2021; Travieso et al., 2022; Rai et al., 2024; Li et al., 2022).

Viral Vector Vaccines

Use a harmless virus as a delivery system (vector) to carry genetic material of the target pathogen.
The body cells produce the antigen, triggering immune response.
Induce strong humoral and cellular immunity.
Effectiveness may be influenced by pre-existing immunity to the vector virus (Travieso et al., 2022; Tang et al., 2025; Aida et al., 2021; Acosta-Coley et al., 2022).

Immunization Schedule

Immunization schedules are organized plans that show which vaccines should be given, at what age, and when booster or maternal doses are needed. These schedules are regularly updated according to new scientific evidence, disease trends, and vaccine recommendations (Diseases, 2023; Byington, 2017; García et al., 2023; O’Leary, 2026; Robinson et al., 2018; Issa et al., 2025).

Childhood Immunization Schedule

Childhood immunization schedules cover vaccines from birth to 18 years of age and include routine, catch-up, and special-condition recommendations (Diseases, 2023; Byington, 2017; García et al., 2023; Wallace et al., 2022; O’Leary, 2026; Robinson et al., 2018; Issa et al., 2025).
Early childhood vaccines are designed to provide protection when children are most vulnerable to infectious diseases (Wallace et al., 2022; Robinson et al., 2018).
Common childhood vaccines include:

DTaP-IPV-Hib-HB (hexavalent vaccine).
Pneumococcal vaccine (PCV).
Rotavirus vaccine.
Meningococcal B (MenB) vaccine.
MMR vaccine.
Varicella vaccine (Wodi et al., 2024).

Many infant vaccines are given in multiple doses, commonly at 2, 4, and 11 months to build strong immunity (Wodi et al., 2024).
Annual influenza vaccination is recommended for children aged 6–59 months in many immunization programs (Wodi et al., 2024).
Vaccine schedules often include:

Primary vaccine series during infancy.
Boosters during early childhood.
Catch-up vaccination if doses are missed (Wallace et al., 2022; Robinson et al., 2018).

Adolescent Immunization

Adolescence is an important stage for additional vaccines and booster protection (Robinson et al., 2020; Robinson et al., 2017; Issa et al., 2025).
Vaccines commonly recommended at 11–12 years include:

Tdap vaccine.
HPV vaccine.
Meningococcal conjugate vaccine (MenACWY) (Robinson et al., 2020; Robinson et al., 2017).

A MenACWY booster is commonly recommended at 16 years to maintain protection (Robinson et al., 2020).
MenB vaccine may be considered between 16–23 years depending on medical advice and risk factors (Robinson et al., 2020; Issa et al., 2025).
Many countries recommend HPV vaccination for all adolescents, often around 12 years of age, to help prevent HPV-related diseases and cancers (Wodi et al., 2024; Robinson et al., 2017).

Adult Immunization

Adult vaccination schedules help maintain immunity and prevent diseases later in life (Robinson et al., 2020; O’Leary, 2026; Robinson et al., 2018).
Adults may need:

Td or Tdap booster doses.
Influenza vaccine.
Pneumococcal vaccine.
Zoster (shingles) vaccine depending on age and health status (Robinson et al., 2020; O’Leary, 2026).

Certain vaccines are recommended for specific risk groups, including older adults, healthcare workers, travelers, or people with chronic illnesses (Robinson et al., 2018).
Adult immunization schedules continue to expand as new vaccines and updated recommendations become available (Robinson et al., 2018).

Maternal Immunization

Maternal immunization protects both pregnant women and newborn infants (Wodi et al., 2024; Robinson et al., 2017; Robinson et al., 2018).
Tdap vaccine is recommended during each pregnancy, usually between 27–36 weeks, to maximize antibody transfer to the baby and protect against pertussis (whooping cough) (Robinson et al., 2020; 2024).
Many countries also recommend influenza vaccination during pregnancy to reduce illness in both mother and infant (Wodi et al., 2024; Robinson et al., 2017; Robinson et al., 2018).
Maternal vaccination is an important part of the life-course immunization approach (Wallace et al., 2022).

Booster Doses

Booster doses are additional vaccine doses given after the primary series to maintain or restore immunity when protection decreases over time (Robinson et al., 2020; Wang et al., 2025; Wodi et al., 2023; Robinson et al., 2017).
Examples of booster vaccination include:

DTaP booster in childhood.
Tdap booster during adolescence.
Td/Tdap booster every 10 years in adults (Robinson et al., 2020; Wodi et al., 2023).

Boosters are especially important for diseases where immunity may wane over time, such as:

Pertussis.
Tetanus.
Diphtheria.
Mumps (Robinson et al., 2020; Wang et al., 2025).

The life-course immunization approach promotes vaccination at every age, including childhood, adolescence, adulthood, pregnancy, and older age, to ensure long-term community protection (Wang et al., 2025; Robinson et al., 2017; Robinson et al., 2018).

Vaccine Administration

Vaccines can be administered through different routes depending on the vaccine type and the immune response needed. The route of administration affects how antigens interact with immune cells and how immunity develops. Proper vaccine storage and cold chain systems are equally important to maintain vaccine potency and effectiveness.

Routes of Vaccine Administration

Vaccines can be administered through:

Intramuscular (IM).
Subcutaneous (SC).
Intradermal (ID).
Oral.
Intranasal (Bouazzaoui & Abdellatif, 2024; Park & Lee, 2021).

The route of administration influences:

Strength of antibody response.
T-cell activation.
Local versus systemic immunity.
Dose-sparing potential (Rosenbaum et al., 2020; Zhao et al., 2023).

Intramuscular (IM)

Intramuscular (IM) injection is the most commonly used vaccine route (Ols et al., 2020; Park & Lee, 2021).
Vaccine is injected directly into the muscle tissue.
Advantages include:

Easy administration.
Good safety profile.
Well tolerated.
Fewer local reactions compared with some other routes (Ols et al., 2020; Park & Lee, 2021).

IM vaccination produces strong and reliable immune responses and is widely used for many routine vaccines (Park & Lee, 2021).

Subcutaneous (SC)

Subcutaneous (SC) injection places vaccine into the fat layer beneath the skin (Ols et al., 2020).
This route is commonly used and continues to be explored for newer vaccines (Ols et al., 2020).
Studies show that IM and SC routes can produce similar long-term antibody and T-cell responses, even when early antigen movement differs (Ols et al., 2020).
In animal studies, IM and SC vaccination provided better survival and tissue protection than oral vaccination for some infections (Mu et al., 2022).

Intradermal (ID)

Intradermal (ID) injection delivers vaccine into the skin layer, which contains many immune cells (Schnyder et al., 2021).
ID vaccination may provide dose-sparing benefits, using only 20–60% of the normal antigen dose while maintaining similar immunity to full-dose IM or SC vaccines (Schnyder et al., 2021).
This approach has shown effectiveness for vaccines such as:

Influenza.
Rabies.
Hepatitis B (, 2020; Schnyder et al., 2021).

Advantages of ID route include:

Efficient stimulation of skin immune cells.
Potential lower vaccine dose requirement.
Strong antibody and T-cell responses (Zhao et al., 2023; Rosenbaum et al., 2020).

Limitations include:

More minor local reactions.
Greater technical skill needed for administration.

Oral

Oral vaccines are taken through the mouth and stimulate immunity in the digestive tract (Bouazzaoui & Abdellatif, 2024; Park & Lee, 2021).
Oral vaccination can produce:

Local mucosal IgA immunity.
Systemic immune responses (Bouazzaoui & Abdellatif, 2024; Zhao et al., 2023).

This route is especially useful for diseases affecting the intestinal or gastrointestinal system (Bouazzaoui & Abdellatif, 2024).
In some animal studies, oral vaccines generated weaker protection than IM or SC administration (Mu et al., 2022).

Intranasal

Intranasal vaccines are delivered through the nose and target the respiratory mucosal surface (Bouazzaoui & Abdellatif, 2024; Park & Lee, 2021).
They stimulate both:

Local mucosal immunity (IgA).
Systemic immunity (Bouazzaoui & Abdellatif, 2024; Zhao et al., 2023).

Intranasal delivery is particularly useful for respiratory infections such as:

Influenza.
SARS-CoV-2 (Bouazzaoui & Abdellatif, 2024; Park & Lee, 2021).

Although promising, intranasal vaccine technology is still less developed than traditional IM vaccination for many diseases (Bouazzaoui & Abdellatif, 2024; Park & Lee, 2021).

Vaccine Storage and Cold Chain

Vaccines must be stored and transported under strict temperature conditions to maintain potency and effectiveness (Pambudi et al., 2021; Hanson et al., 2017).
Exposure to temperatures outside the recommended range can reduce vaccine efficacy (Pambudi et al., 2021; Hanson et al., 2017).
Most traditional vaccines are stored at 2–8 °C, while some mRNA COVID-19 vaccines require −30 °C to −80 °C storage (Fahrni et al., 2022; Pambudi et al., 2021; Sun et al., 2022; James, 2021).
Maintaining these temperatures creates significant cold chain challenges, especially in rural and low-resource settings (Fahrni et al., 2022; Pambudi et al., 2021).
Common cold chain problems include:

Heat exposure.
Freezing damage.
Temperature fluctuations during transport and storage (Fahrni et al., 2022; Sinnei et al., 2023; Kartoglu & Ames, 2022; Gaievskyi et al., 2026; Hanson et al., 2017).

Effective cold chain management requires:

Reliable refrigeration systems.
Temperature monitoring devices.
Vaccine vial monitors and data loggers.
Staff training and maintenance programs (Kartoglu & Ames, 2022; Fahrni et al., 2022; Sinnei et al., 2023; Gaievskyi et al., 2026).

Climate change, electricity shortages, and weak infrastructure continue to threaten vaccine cold chain systems worldwide, particularly in low- and middle-income countries (Fahrni et al., 2022; Pambudi et al., 2021; Ayowole et al., 2025; Hanson et al., 2017).

Mechanism of Vaccine-Induced Immunity

Vaccines protect the body by safely mimicking infection and activating the adaptive immune system. This process involves antigen recognition, antibody production, memory cell formation, and long-term immune protection. Through these coordinated responses, vaccines prepare the immune system to respond rapidly and effectively when the real pathogen is encountered.

Antigen Recognition

Antigen recognition is the first stage of vaccine-induced immunity. Vaccines introduce harmless antigens—such as weakened microbes, microbial proteins, or genetic instructions encoding antigens—that are detected by the immune system.

Vaccine antigens are recognized by naïve B cells and T cells, initiating immune activation and clonal expansion (Lam et al., 2024; Sette & Crotty, 2022; Goel et al., 2021; Wang et al., 2022).
B cell receptors (BCRs) bind directly to antigens, while T cell receptors (TCRs) recognize processed antigen fragments presented by antigen-presenting cells (APCs) such as dendritic cells (Lam et al., 2024; Sette & Crotty, 2022).
Following antigen recognition, immune cells undergo activation, proliferation, and differentiation, producing specialized effector and memory populations (Goel et al., 2021; Tarke et al., 2022).
The innate immune system supports this process through cytokines, inflammatory signals, and antigen presentation, helping shape the quality and magnitude of the adaptive response (Palgen et al., 2021; Bhattacharya, 2022; Wang et al., 2022).

Research consistently shows strong evidence that vaccination reliably induces antigen-specific B- and T-cell responses, which form the basis of protective immunity (Lam et al., 2024; Goel et al., 2021; Sette & Crotty, 2022; Tarke et al., 2022).

Antibody Production

Once immune cells are activated, vaccines stimulate the production of antibodies that provide immediate protection.

Activated B cells differentiate into plasmablasts and plasma cells, which secrete antibodies shortly after vaccination (Goel et al., 2021; Terreri et al., 2022; Ciabattini et al., 2021).
Many vaccines generate high levels of IgG antibodies, particularly IgG1, which rise after vaccination and peak following booster doses before gradually declining (Terreri et al., 2022; Bozhkova et al., 2025; Wang et al., 2022).
Some antibodies are neutralizing antibodies, meaning they block pathogens from infecting host cells and are strongly associated with vaccine protection (Horns et al., 2020; Goel et al., 2021; Brasu et al., 2022).
Within lymphoid tissues, germinal center reactions promote affinity maturation, where B cells evolve to produce antibodies with greater strength and sometimes broader recognition of variants (Palm & Henry, 2019; Andrews et al., 2019; Goel et al., 2021).

Antibody responses provide rapid defense against infection and are often the first measurable sign of successful vaccination.

Memory Cell Formation

Long-lasting immunity depends on the development of immune memory.

Vaccination generates memory B cells that persist after antibody levels decline and can rapidly produce antibodies during future exposures (Lam et al., 2024; Palm & Henry, 2019; Goel et al., 2021; Ciabattini et al., 2021).
Many vaccines also produce long-lived plasma cells, which continue secreting protective antibodies for months or years (Terreri et al., 2022; Bozhkova et al., 2025).
Memory CD4 and CD8 T cells are formed alongside memory B cells and provide additional protection by coordinating immune responses and destroying infected cells (Sette & Crotty, 2022; Painter et al., 2023; Tarke et al., 2022).
T follicular helper (Tfh) cells are especially important because they support B-cell maturation and help generate stronger, high-affinity antibody responses (Lam et al., 2024; Brasu et al., 2022).
Prior infection or previous vaccination may shape immune memory, a phenomenon sometimes called hybrid immunity, which can broaden or alter immune protection (Inoue & Kurosaki, 2023; Rodda et al., 2022; Quast & Tarlinton, 2021).

Memory cell formation ensures that the immune system retains information about the pathogen long after vaccination.

Long-Term Protection

Long-term protection is the final outcome of vaccine-induced immunity and depends on both antibodies and immune memory.

Serum antibody levels generally peak after vaccination and then decline over time (Goel et al., 2021; Terreri et al., 2022; Ciabattini et al., 2021).
Despite declining antibodies, memory B cells and memory T cells often persist for months to years, maintaining immune readiness (Lam et al., 2024; Palm & Henry, 2019; Bozhkova et al., 2025).
Memory B cells can rapidly produce new antibodies upon re-exposure, while memory T cells provide cross-variant and cellular protection, reducing disease severity even when infection occurs (Brasu et al., 2022; Sette & Crotty, 2022; Rodda et al., 2022).
Booster doses help reactivate immune memory, increasing antibody titers and strengthening protection when immunity wanes (Palgen et al., 2021; Painter et al., 2023).

The durability of vaccine protection varies depending on the vaccine type, pathogen, and host immune factors, but immune memory remains the cornerstone of sustained protection.

Benefits of Immunization

Immunization is one of the most successful public health interventions worldwide. Vaccination provides protection not only to individuals but also to communities and societies by reducing disease burden, preventing deaths, and generating major social and economic benefits.

Prevention of Infectious Diseases

Vaccines prevent infectious diseases by preparing the immune system to recognize and rapidly respond to pathogens before severe illness develops (Orenstein & Ahmed, 2017; Andre et al., 2008).
Immunization programs have reduced or eliminated many vaccine-preventable diseases by more than 90–99% in countries with high vaccine coverage (Orenstein & Ahmed, 2017; Pezzotti et al., 2018).
Vaccines have contributed to the eradication of smallpox and the elimination of certain poliovirus types globally (Andre et al., 2008; Montero et al., 2024; Shattock et al., 2024).
Long-term national immunization programs have prevented millions of cases of diseases such as measles, diphtheria, pertussis, and polio (Pezzotti et al., 2018; Shukla & Shah, 2018).
Some vaccines may provide broader immune benefits beyond their target pathogen. For example, measles vaccination has been associated with improved immune memory and reduced susceptibility to other infections (Betsch et al., 2017).

Reduction in Morbidity and Mortality

Vaccination significantly lowers disease severity, disability, hospitalization, and death caused by infectious diseases (Alanazi et al., 2024; Orenstein & Ahmed, 2017).
In a single United States birth cohort, vaccination prevented approximately 20 million illnesses and more than 40,000 deaths (Orenstein & Ahmed, 2017).
Globally, vaccines are estimated to prevent 3.5–5 million deaths annually from diseases such as measles, tetanus, diphtheria, influenza, and pertussis (Andre et al., 2008; Montero et al., 2024; Shattock et al., 2024).
Modeling of 50 years of the WHO Expanded Programme on Immunization estimated approximately 154 million deaths prevented, with vaccines contributing substantially to reductions in infant mortality worldwide (Shattock et al., 2024).
Vaccines also prevent long-term complications and chronic conditions linked to infection, including hepatocellular carcinoma through hepatitis B vaccination and cervical cancer through HPV vaccination (Andre et al., 2008).
Reduced hospitalization and fewer severe infections lessen the burden on health-care systems and improve overall population health (Chevalier-Cottin et al., 2020; Doherty et al., 2016).

Herd Immunity

Herd immunity (community protection) occurs when sufficient vaccination coverage reduces disease transmission, indirectly protecting people who are not vaccinated (Doherty et al., 2016; Shattock et al., 2024).
Unlike most medical treatments, vaccines provide both individual and population-level protection by interrupting chains of infection (Santosa et al., 2024; Doherty et al., 2016).
Herd immunity is particularly important for individuals who cannot receive vaccines, such as newborns, immunocompromised people, and those with medical contraindications (Doherty et al., 2016; Nandi & Shet, 2020).
Reduced pathogen circulation lowers disease outbreaks and decreases the risk of epidemics within communities (Shattock et al., 2024; Santosa et al., 2024).
Economic and epidemiological models consistently show that including herd effects increases the estimated effectiveness and cost-benefit of vaccination programs (Brisson & Edmunds, 2003; Simoens et al., 2024).
Public communication about herd immunity and collective protection can improve vaccine acceptance and encourage socially responsible vaccination behavior (Betsch et al., 2017; Arnesen et al., 2018; Betsch et al., 2013).

Economic and Social Benefits

Vaccination programs generate substantial economic returns by preventing disease and reducing health-care expenses (Andre et al., 2008; Deogaonkar et al., 2012).
Studies estimate 12–18% annual economic returns and benefit-cost ratios reaching 44:1 in some low- and middle-income countries (Andre et al., 2008; Chevalier-Cottin et al., 2020; Deogaonkar et al., 2012).
Immunization lowers medical treatment costs, reduces out-of-pocket expenses, and prevents catastrophic health expenditure for families (Doherty et al., 2016; Andre et al., 2008; Deogaonkar et al., 2012).
Reduced illness leads to fewer missed workdays and caregiving responsibilities, improving workforce productivity and reducing absenteeism (Montero et al., 2024; Chevalier-Cottin et al., 2020).
Healthier children experience improved cognitive development, school attendance, educational attainment, and lifetime earning potential (Nandi & Shet, 2020; Santosa et al., 2024; Doherty et al., 2016).
Vaccination contributes to social equity because health and economic gains are often greatest among poorer and vulnerable populations, helping reduce disparities (Andre et al., 2008; Santosa et al., 2024).
Prevention of outbreaks supports safer travel, trade, and global economic stability, reducing disruptions caused by epidemics and pandemics (Doherty et al., 2016; Montero et al., 2024).

Common Vaccine-Preventable Diseases

Measles

Highly contagious viral disease causing fever, rash, cough, and complications such as pneumonia and encephalitis (Frenkel, 2021; Yamamoto, 2020).
Controlled through Measles vaccine or MMR/MR vaccine (Frenkel, 2021; Kitano, 2021).
Large outbreaks occur when vaccination coverage declines (Kouamou & Inzaule, 2023; Maugeri et al., 2024).
Measles vaccination has prevented millions of deaths globally and contributed significantly to reductions in child mortality (Montero et al., 2024; McCarthy et al., 2025).
Recent immunity gaps and vaccine hesitancy have caused re-emergence in several regions (Parums, 2024; Maugeri et al., 2024).

Polio

Viral disease that can cause permanent paralysis and death (Yamamoto, 2020; Montero et al., 2024).
Prevented through Inactivated Polio Vaccine (IPV) and Oral Polio Vaccine (OPV) (Kitano, 2021; Hasan et al., 2024).
Global vaccination programs have nearly eradicated polio, although outbreaks persist in low-coverage areas (Montero et al., 2024; Kouamou & Inzaule, 2023).
COVID-19-related disruptions delayed vaccination campaigns and increased outbreak risks (Ho et al., 2022; Feldman et al., 2021).

Hepatitis B

Viral infection affecting the liver and may lead to chronic hepatitis, cirrhosis, and liver cancer (Yamamoto, 2020; Hasan et al., 2024).
Prevented using the Hepatitis B (HepB) vaccine (Kitano, 2021; Hasan et al., 2024).
Birth-dose and routine childhood vaccination reduce transmission and long-term liver complications (Montero et al., 2024).
Vaccination has helped lower rates of hepatocellular carcinoma associated with chronic infection (Montero et al., 2024).

Tetanus

Serious bacterial disease caused by Clostridium tetani, leading to painful muscle spasms and respiratory failure (Yamamoto, 2020; Vishnoi et al., 2020).
Prevented through Tetanus toxoid-containing vaccines included in DTP/DTaP/Td/Tdap schedules (Kitano, 2021; Montero et al., 2024).
Maternal and neonatal tetanus vaccination programs have greatly reduced deaths worldwide (Montero et al., 2024).
Risk increases where immunization and booster coverage are inadequate (Maugeri et al., 2024; Rachlin et al., 2022).

Diphtheria

Bacterial infection causing throat inflammation, breathing difficulties, and toxin-mediated organ damage (Yamamoto, 2020; Vishnoi et al., 2020).
Prevented through Diphtheria-containing vaccines such as DTP/DTaP (Kitano, 2021; Maugeri et al., 2024).
Routine vaccination has dramatically lowered incidence globally (Montero et al., 2024).
Coverage decline can lead to localized outbreaks and severe disease (Rachlin et al., 2022; Maugeri et al., 2024).

Pertussis (Whooping Cough)

Highly contagious bacterial respiratory infection characterized by severe coughing spells (Frenkel, 2021; Yamamoto, 2020).
Prevented through Pertussis-containing vaccines within DTP/DTaP/Tdap immunization schedules (Kitano, 2021; Maugeri et al., 2024).
Particularly dangerous for infants and young children (Frenkel, 2021; Vishnoi et al., 2020).
Waning immunity and reduced vaccine uptake may contribute to disease resurgence (Maugeri et al., 2024; Parums, 2024).

Tuberculosis

Infectious disease caused by Mycobacterium tuberculosis, primarily affecting the lungs (Yamamoto, 2020).
Prevented partially through the BCG vaccine, especially against severe childhood TB (Rachlin et al., 2022; Hasan et al., 2024).
BCG remains part of routine infant immunization programs in many countries (Hasan et al., 2024).
Healthcare workers and vulnerable populations remain at increased risk (Hasan et al., 2024).

Influenza

Seasonal viral respiratory disease associated with significant morbidity and mortality (Frenkel, 2021; Sun et al., 2021).
Prevented using seasonal influenza vaccines, including inactivated and live-attenuated influenza vaccines (LAIV) (Kitano, 2021; Hasan et al., 2024).
Vaccination is particularly important for high-risk groups such as older adults, children, pregnant women, and healthcare workers (Hasan et al., 2024; Root-Bernstein, 2021).
Influenza contributes a substantial annual disease burden globally (Sun et al., 2021; Kitano, 2021).

COVID-19 and Other Emerging Diseases

COVID-19 vaccines, including mRNA, viral vector, and other platforms, have become essential public health tools (Excler et al., 2021; Sellner et al., 2021).
Vaccination reduces severe disease, hospitalization, and mortality from SARS-CoV-2 infection (Sellner et al., 2021).
WHO now recommends COVID-19 vaccination for healthcare workers and vulnerable populations (Hasan et al., 2024).
Emerging diseases such as Ebola, MERS, Lassa fever, and Nipah virus are major targets for rapid vaccine development (Excler et al., 2021).
Declining vaccine uptake and hesitancy may increase the risk of outbreaks involving COVID-19 variants and other vaccine-preventable diseases (Parums, 2024; Montero et al., 2024).

Vaccine Safety and Side Effects

Vaccine Safety Monitoring

Vaccines undergo extensive clinical testing before approval, but rare or delayed side effects may only become evident after millions of doses are administered, making post-marketing safety monitoring essential (Rudolph et al., 2022; Wasiullah et al., 2025).
Pharmacovigilance (PV) involves the detection, assessment, understanding, and prevention of vaccine-related adverse effects and safety concerns (Rudolph et al., 2022; Wasiullah et al., 2025).
Vaccine safety monitoring uses two major approaches:

Passive surveillance, which depends on spontaneous reporting of adverse events
Active surveillance, which involves systematic follow-up and linkage of health databases to detect safety signals more effectively (Rudolph et al., 2022; Alghamdi et al., 2021; Salmon et al., 2024; Gee et al., 2024; Phillips et al., 2021; Oosterhuis et al., 2022).

The COVID-19 vaccination campaign accelerated pharmacovigilance expansion, improving international collaboration, real-time safety monitoring, and transparent communication of vaccine safety findings (Rudolph et al., 2022; Alghamdi et al., 2021; Salmon et al., 2024; Gee et al., 2024; Oosterhuis et al., 2022).
Experiences from countries such as the United States, Netherlands, Ethiopia, Pakistan, and Uganda show that electronic reporting systems, expert committees, and strengthened surveillance programs improve the timely detection and management of Adverse Events Following Immunization (AEFIs) (Hagos et al., 2024; Cole et al., 2022; Nambasa et al., 2025; Salmon et al., 2024; Gee et al., 2024; Oosterhuis et al., 2022).

Common Side Effects

Most vaccine side effects are mild, temporary, and self-limiting, usually occurring within 24–48 hours after vaccination and resolving within a few days (Padilla-Flores et al., 2024; Abukhalil et al., 2023; Ashie et al., 2026; Andrzejczak-Grządko et al., 2021; Saeed et al., 2021; Mohebbi et al., 2023; Dighriri et al., 2022).
Common local reactions include:

Injection-site pain
Redness
Swelling
These reactions occur due to local immune activation and are generally mild (Padilla-Flores et al., 2024; Dighriri et al., 2022).

Common systemic reactions include:

Fatigue
Headache
Muscle pain (myalgia)
Chills
Low-grade fever
These symptoms reflect immune system activation and typically resolve without complications (Abukhalil et al., 2023; Andrzejczak-Grządko et al., 2021; Saeed et al., 2021).

Mild allergic reactions may occur and can include:

Rash
Pruritus (itching)
Transient hypersensitivity reactions
These are usually mild and manageable (Abukhalil et al., 2023; Abdurrahman & Putman, 2023; Dighriri et al., 2022).

Severe allergic reactions, such as anaphylaxis, are extremely rare but require immediate medical management and post-vaccination observation procedures are designed to identify and treat them rapidly (Abdurrahman & Putman, 2023; Wasiullah et al., 2025).
Studies involving Pfizer-BioNTech (BNT162b2) and Sinopharm vaccines reported that most side effects were short-lived, non-serious, and rarely associated with hospitalization or prolonged work absence (Abukhalil et al., 2023; Saeed et al., 2021; Mohebbi et al., 2023).

Rare Adverse Events

Vaccines have a strong safety profile overall, but very rare immune-mediated adverse events may become detectable after large-scale use (Padilla-Flores et al., 2024; Stone et al., 2019; Yang et al., 2024).
Rare reported adverse events include:

Myocarditis
Vaccine-induced thrombotic thrombocytopenia (VITT)
Guillain–Barré syndrome (GBS)
Transverse myelitis
These complications occur at very low frequencies (Padilla-Flores et al., 2024; Stone et al., 2019; Yang et al., 2024).

Evidence indicates that:

Myocarditis has been reported more frequently following mRNA vaccines
Thrombotic events, including VITT, have been more commonly associated with viral vector vaccines (Yang et al., 2024).

VITT may involve cerebral venous sinus thrombosis and can have significant mortality if diagnosis and treatment are delayed (Yang et al., 2024).
Large pharmacovigilance systems, including U.S. vaccine surveillance programs and the Dutch Lareb system, rapidly identified these rare events and contributed to updated clinical guidance and vaccination recommendations (Rudolph et al., 2022; Gee et al., 2024; Oosterhuis et al., 2022).

Managing Post-Vaccination Reactions

Management of vaccine reactions depends on the severity and nature of symptoms.
Mild reactions generally require only supportive care and usually resolve within a few days (Abukhalil et al., 2023; Andrzejczak-Grządko et al., 2021; Saeed et al., 2021; Mohebbi et al., 2023; Dighriri et al., 2022).
Recommended measures for mild reactions include:

Rest
Adequate hydration
Analgesics or antipyretics for pain and fever relief
Observation until symptoms improve (Abukhalil et al., 2023; Dighriri et al., 2022).

Serious adverse events require prompt medical evaluation and treatment (Padilla-Flores et al., 2024; Stone et al., 2019; Yang et al., 2024).
Warning signs that require urgent medical attention include:

Chest pain
Shortness of breath (dyspnea)
Persistent neurological symptoms
Severe allergic manifestations (Padilla-Flores et al., 2024; Yang et al., 2024).

Clinical management may involve:

Laboratory testing
Imaging studies
Specialist consultation
Hospital treatment for conditions such as myocarditis, VITT, or Guillain–Barré syndrome (Padilla-Flores et al., 2024; Stone et al., 2019; Yang et al., 2024).

National causality assessment committees investigate serious AEFIs and may recommend enhanced monitoring, revised guidance, or, in rare cases, restrictions on vaccine use (Hagos et al., 2024; Gee et al., 2024).

Vaccine Hesitancy and Myths

Causes of Vaccine Hesitancy

Vaccine hesitancy is considered a major global public health concern and is mainly driven by lack of confidence, complacency, and access barriers, rather than vaccine availability alone (Htike et al., 2025; Gerretsen et al., 2021; Nwachukwu et al., 2024).
The 3C/5C models explain vaccine hesitancy through factors such as:

Confidence (trust).
Complacency (low perceived disease risk).
Convenience or constraints (access barriers) (Schmid et al., 2017; Wang et al., 2025; Sheikh et al., 2021).

Confidence (Trust-Related Factors)

Fear of side effects and doubts about vaccine effectiveness and benefits are among the strongest predictors of vaccine hesitancy across COVID-19 and influenza vaccines (Htike et al., 2025; Gerretsen et al., 2021; Nwachukwu et al., 2024; Schmid et al., 2017; Wang et al., 2025; Sheikh et al., 2021; Razai et al., 2021).
Many individuals express mistrust toward:

Governments
Health authorities
Pharmaceutical companies
The vaccine development process (Nwachukwu et al., 2024; Karafillakis & Larson, 2017; Schmid et al., 2017; Wang et al., 2025; Lewis, 2025).

A common concern is the belief that vaccines, especially COVID-19 vaccines, were developed “too quickly” and therefore may not have been adequately tested for safety (Htike et al., 2025; Karafillakis & Larson, 2017; Sheikh et al., 2021; Razai et al., 2021).

Complacency (Low Perceived Need)

Individuals who believe that infectious diseases are not serious or that they are personally at low risk are less likely to accept vaccination (Htike et al., 2025; Gerretsen et al., 2021; Nwachukwu et al., 2024; Schmid et al., 2017; Wang et al., 2025; Myburgh et al., 2023).
Preference for natural immunity, alternative therapies, or reliance on non-pharmaceutical measures can reduce motivation to vaccinate (Htike et al., 2025; Gerretsen et al., 2021; Myburgh et al., 2023).
Convenience and Access Barriers
Practical barriers that contribute to hesitancy include:

Long distance to vaccination centers
Transportation difficulties
Financial costs
Complicated registration systems
Limited clinic opening hours (Htike et al., 2025; Robinson et al., 2022; Wang et al., 2025; Myburgh et al., 2023).

These barriers may reduce vaccine uptake even among individuals who are willing to be vaccinated (Robinson et al., 2022).

Other Contributing Factors

Sociodemographic and psychological factors associated with vaccine hesitancy include:

Younger age
Lower education level
Political ideology
Depression or anxiety
Needle phobia (Gerretsen et al., 2021; Zhao et al., 2022; Wang et al., 2025).

However, these factors generally explain less hesitancy compared with concerns about safety and trust (Gerretsen et al., 2021).

Common Misconceptions About Vaccines

Safety and Ingredient Myths

Concerns about vaccine ingredients are widespread and commonly involve:

Aluminum adjuvants
Mercury (thiomersal)
Formaldehyde
DNA fragments
The belief that “too many vaccines” overload the immune system (Geoghegan et al., 2020; Löffler, 2021; Conklin et al., 2021).

Persistent myths falsely claim that vaccines can cause:

Autism
Infertility
Diabetes
Developmental disorders
Attention disorders
Autoimmune diseases
Death (Geoghegan et al., 2020; Löffler, 2021; Sheikh et al., 2021; Conklin et al., 2021).

COVID-19 Vaccine Misconceptions

Common COVID-19 vaccine myths include beliefs that:

Vaccines contain live virus and can cause COVID-19 infection
Clinical trials involved only a small number of participants
Serious side effects are common and widespread (Kreps et al., 2021).

Online misinformation and conspiracy theories frequently promote claims involving:

Microchips
Population control
Hidden political motives
Violations of personal freedom or liberty (Whitehead et al., 2023; Zhao et al., 2022; Myburgh et al., 2023).

Influenza Vaccine Misconceptions

A common misconception about influenza vaccines is the belief that the flu vaccine causes influenza infection or that the vaccine is ineffective (Schmid et al., 2017).

Scientific Facts and Evidence

Evidence Supporting Vaccine Safety

Vaccines undergo:

Extensive laboratory testing
Multi-phase clinical trials
Continuous post-marketing safety monitoring before and after approval (Geoghegan et al., 2020; Conklin et al., 2021; Lewis, 2025).

Global reviews by scientific experts and health organizations consistently show no credible evidence linking routine vaccines to:

Autism
Autoimmune diseases
Infertility
Immune system overload
Serious chronic illnesses (Geoghegan et al., 2020; Löffler, 2021; Conklin et al., 2021).

Scientific reviews evaluating concerns regarding aluminum, mercury, formaldehyde, and genetic vaccine technologies conclude that vaccines remain among the safest and most cost-effective medical interventions available (Löffler, 2021; Conklin et al., 2021).

Evidence Supporting Vaccine Effectiveness

Vaccines have dramatically reduced the incidence of many infectious diseases and have prevented millions of deaths worldwide (, 2021).
Vaccination programs have contributed to the control or near-elimination of diseases such as:

Measles
Polio
Diphtheria
Tetanus
Pertussis (Geoghegan et al., 2020; Conklin et al., 2021).

Misinterpretation of vaccine efficacy statistics may falsely reduce public confidence, even though vaccines substantially lower the risk of severe disease, hospitalization, and death (, 2021).

Evidence on Misinformation

Systematic reviews show that misinformation and conspiracy theories circulating online significantly increase vaccine hesitancy and reduce vaccine confidence (Whitehead et al., 2023; Zhao et al., 2022; Myburgh et al., 2023; Lewis, 2025).
Research indicates that:

Clear scientific communication
Trusted healthcare professionals
Transparent safety reporting
Easier vaccine access
are essential strategies for improving vaccine confidence and correcting misinformation (Whitehead et al., 2023; Razai et al., 2021; Lewis, 2025).

Challenges in Immunization Programs

Access and Availability

Geographic and financial barriers:

Long distances to health facilities, transportation difficulties, and out-of-pocket expenses contribute to missed or incomplete vaccination, particularly in rural areas and low- and middle-income countries (LMICs) (Bangura et al., 2020; Haldane et al., 2023; Musuka et al., 2025).
Rural and underserved populations often face reduced physical access to vaccination services, limiting routine immunization coverage (Bangura et al., 2020; Musuka et al., 2025).

Health system limitations:

Workforce shortages, poorly organized vaccination sessions, and inadequate clinic infrastructure reduce effective vaccine delivery and accessibility (Bangura et al., 2020; Haldane et al., 2023; Kholina et al., 2022; Shimp et al., 2023).
Vaccination site designs may unintentionally exclude vulnerable groups, including people with disabilities and marginalized communities (Kholina et al., 2022; Shimp et al., 2023).

Supply shortages and instability:

Vaccine stock-outs and unstable supply chains, including shortages of HPV, malaria, and COVID-19 vaccines, disrupt immunization programs and weaken public confidence (Fousseni et al., 2025; Haldane et al., 2023; Santangelo et al., 2024; Khairi et al., 2022).
Weak procurement systems and delayed deliveries can interrupt immunization schedules and reduce uptake (Khairi et al., 2022; Santangelo et al., 2024).

Cold Chain Maintenance

Cold chain failures:

Weak cold-chain systems, interrupted distribution networks, and lack of functional refrigeration remain major barriers, especially during last-mile delivery (Bangura et al., 2020; Fousseni et al., 2025; Kahn et al., 2024; Haldane et al., 2023; Tinessia et al., 2025; Talbot et al., 2024; Pambudi et al., 2021).
Temperature excursions during transport or storage may compromise vaccine potency and effectiveness (Pambudi et al., 2021; Kahn et al., 2024).

Ultra-cold storage challenges:

Some COVID-19 vaccines require ultra-cold temperatures, creating logistical difficulties for remote and resource-limited settings with unreliable electricity and transport systems (Haldane et al., 2023; Dagovetz et al., 2025; Khairi et al., 2022; Tinessia et al., 2025; Pambudi et al., 2021).
Cold-chain disparities contribute to inequitable vaccine access globally (Talbot et al., 2024).

Strategies for improvement:

Recommended approaches include improved refrigeration equipment, digital monitoring systems, thermostable vaccines, mobile cold storage, and better financing and planning (Kahn et al., 2024; Fousseni et al., 2025; Tinessia et al., 2025; Pambudi et al., 2021; Yang et al., 2025).

Public Awareness

Knowledge gaps and mistrust:

Lack of caregiver knowledge, misconceptions, and distrust in vaccines or immunization programs reduce vaccine acceptance and uptake (Bangura et al., 2020; Santangelo et al., 2024; Strully et al., 2021; Fatinah et al., 2026; Adumashi et al., 2026).
Limited health literacy and misunderstanding of vaccine benefits contribute to delayed or refused vaccination (Fatinah et al., 2026; Adumashi et al., 2026).

Misinformation and communication problems:

Politicized or inconsistent messaging and widespread misinformation on social media increase hesitancy and reduce confidence in immunization programs (Santangelo et al., 2024; Strully et al., 2021; Dagovetz et al., 2025; Adumashi et al., 2026).
Rumors and misinformation may spread faster than evidence-based health communication, particularly during outbreaks and emergency vaccination campaigns (Dagovetz et al., 2025; Adumashi et al., 2026).

Community engagement approaches:

Community-based and culturally tailored communication strategies, including involvement of trusted leaders and local health workers, can improve vaccine demand and counter hesitancy (Strully et al., 2021; Santangelo et al., 2024; Fatinah et al., 2026; Musuka et al., 2025).
Trust-building efforts are particularly effective among minority and marginalized populations (Strully et al., 2021; Musuka et al., 2025).

Global Health Inequalities

Between-country inequalities:

High-income countries secured early and larger vaccine supplies, whereas many LMICs experienced shortages and short-expiry donations that disrupted coverage and planning (Santangelo et al., 2024; Haldane et al., 2023; Dagovetz et al., 2025; Khairi et al., 2022).
Unequal purchasing power and manufacturing concentration contributed to global disparities in vaccine access (Khairi et al., 2022; Dagovetz et al., 2025).

Within-country inequalities:

Lower-income groups, rural populations, migrants, minorities, and people with disabilities face greater structural and informational barriers, resulting in lower vaccine coverage and higher numbers of “zero-dose” children (Kholina et al., 2022; Haldane et al., 2023; Musuka et al., 2025; Tinessia et al., 2025; Santangelo et al., 2024; Adumashi et al., 2026).
Social stigma and exclusion further widen immunization gaps in vulnerable populations (Tinessia et al., 2025; Musuka et al., 2025).

Equity-focused solutions:

Addressing inequalities requires fair vaccine allocation, inclusive vaccination policies, infrastructure investment, workforce strengthening, and sustained international collaboration such as Gavi and COVAX initiatives (Santangelo et al., 2024; Haldane et al., 2023; Dagovetz et al., 2025; Shimp et al., 2023; Tinessia et al., 2025; Yang et al., 2025).

Immunization Programs and Global Initiatives

National Immunization Programs

National immunization programs are built on public–private partnerships involving governments, health departments, healthcare providers, and vaccine manufacturers. In the United States, agencies such as the CDC and advisory committees coordinate vaccination schedules, safety surveillance, and program implementation (Roper et al., 2021).
Countries regularly review and revise vaccine schedules to optimize timing and dosage while maintaining protection. For example, the Netherlands evaluated its immunization schedule and proposed reducing certain polio and tetanus doses and adjusting MMR timing for improved efficiency and protection (Pluijmaekers et al., 2024).
Simplified vaccination schedules, including combination vaccines and fewer clinic visits, improve vaccine uptake. Singapore’s revised childhood immunization schedule increased catch-up vaccination rates among children by approximately 2–5 percentage points (Tan et al., 2023).
Financial support mechanisms such as the Vaccines for Children (VFC) program in the United States reduce economic barriers and generate major public health and economic benefits (Zhou et al., 2024; Roper et al., 2021).

Role of International Health Organizations

International organizations have played a central role in global immunization progress. The WHO Expanded Programme on Immunization (EPI) and later initiatives such as Universal Childhood Immunization (UCI), the Global Polio Eradication Initiative, Gavi, and COVAX increased vaccine coverage from less than 5% in the 1970s to around 80% for core childhood vaccines by 1990 and contributed to an estimated 154 million lives saved over five decades (Lindstrand et al., 2021; Nunes et al., 2024; De Melo Araújo et al., 2025).
Gavi, the Vaccine Alliance, has improved access to newer vaccines in low-income countries, strengthened national health systems, and supported vaccination of more than one billion children, potentially preventing over 17 million deaths (Lindstrand et al., 2021; Jeon & Kim, 2025).
The Immunization Agenda 2030 (IA2030) provides a global framework endorsed by WHO member states with the goal that “everyone, everywhere, at every age” benefits from vaccines. Its priorities include equity, financing, innovation, outbreak response, and integrated service delivery (Lindstrand et al., 2021; Jeon & Kim, 2025).
Global vaccine partnerships involving governments, UN agencies, foundations, and private organizations support vaccine research, financing, and delivery but also raise concerns regarding governance, transparency, and accountability within the global vaccine ecosystem (Nunes et al., 2024; Moradpour et al., 2023; Jeon & Kim, 2025).

Global Vaccination Campaigns

Mass vaccination and catch-up campaigns have been highly effective in controlling vaccine-preventable diseases. Regional efforts coordinated by organizations such as PAHO successfully eliminated rubella and congenital rubella syndrome in the Americas through large-scale MMR and rubella vaccination campaigns (Hardt et al., 2016).
National immunization days and integrated campaigns combining vaccines with interventions such as vitamin A supplementation or insecticide-treated bed nets help reach remote and underserved populations in many low- and middle-income countries (Hardt et al., 2016; Ahmed et al., 2023).
During the COVID-19 pandemic, mass-vaccination strategies prioritized healthcare workers, older adults, and high-risk groups, contributing to reductions in infections and mortality where high coverage was achieved, although implementation challenges related to staffing, communication, and cold-chain capacity remained significant (Hasan et al., 2021).
Integrated vaccination campaigns are generally effective when planning, logistics, and resources are well coordinated, increasing coverage and community engagement, although they may place additional burdens on frontline healthcare workers if not adequately supported (Ahmed et al., 2023).

Recent Advances in Immunization

Novel Vaccine Technologies

Recent advances in immunization have been driven by novel vaccine platforms, particularly mRNA, viral vector, recombinant protein, and nanoparticle-based vaccines, which allow faster development and scalable production (Jeon & Kim, 2025; Moradpour et al., 2023).
The rapid development of COVID-19 vaccines demonstrated the effectiveness of modern vaccine technologies and accelerated innovation in vaccine research, manufacturing, and regulatory pathways (Jeon & Kim, 2025; Moradpour et al., 2023).
New vaccine technologies are increasingly being incorporated into national immunization schedules, reflecting growing evidence of their safety, effectiveness, and public health value (De Melo Araújo et al., 2025).
Combination vaccines and optimized vaccine formulations continue to improve immunization programs by reducing the number of injections and clinic visits while maintaining strong protection (Hardt et al., 2016; Tan et al., 2023).
Advances in vaccine delivery systems, manufacturing platforms, and global vaccine ecosystems support more rapid responses to emerging infectious diseases and future pandemics (Moradpour et al., 2023; Jeon & Kim, 2025).

Personalized Vaccines

Personalized vaccine development is an emerging field that aims to design vaccines tailored to individual genetic, immunologic, or disease characteristics, particularly for cancer and precision medicine applications (Jeon & Kim, 2025).
Advances in genomics, bioinformatics, and immune profiling are helping researchers identify patient-specific antigens and improve targeted immune responses (Jeon & Kim, 2025).
Personalized and precision-based vaccine strategies may enhance protection in populations with differing immune responses, including older adults, immunocompromised individuals, and people with chronic diseases (Jeon & Kim, 2025; Moradpour et al., 2023).
Although personalized vaccines remain largely in developmental and specialized clinical settings, they represent an important direction for future immunization strategies (Jeon & Kim, 2025).

Future Directions in Vaccine Development

Future vaccine development emphasizes pandemic preparedness, faster vaccine design, and platform technologies capable of responding rapidly to newly emerging pathogens (Jeon & Kim, 2025; Moradpour et al., 2023).
Research increasingly focuses on universal and broadly protective vaccines, including vaccines targeting multiple strains or variants to reduce the need for frequent reformulation (Hardt et al., 2016; Jeon & Kim, 2025).
Strengthening global vaccine ecosystems and partnerships is considered essential for ensuring equitable access, financing, manufacturing capacity, and coordinated international responses during health emergencies (Nunes et al., 2024; Moradpour et al., 2023).
Integration of vaccines into national schedules continues to evolve as countries assess evidence, disease burden, cost-effectiveness, and public health priorities when adopting new vaccines (Pluijmaekers et al., 2024; De Melo Araújo et al., 2025).
Long-term progress in immunization will depend on sustained investment in research, surveillance, regulatory innovation, and global cooperation to ensure vaccines remain effective, accessible, and responsive to future health threats (Lindstrand et al., 2021; Jeon & Kim, 2025; Zhou et al., 2024).

Conclusion

Immunization remains one of the most effective and cost-efficient public health interventions, significantly reducing disease burden, disability, and mortality worldwide.
Advances in vaccine technologies, including mRNA, viral vector, recombinant, and nanoparticle platforms, have accelerated vaccine development and improved responsiveness to emerging infectious diseases (Jeon & Kim, 2025; Moradpour et al., 2023).
National immunization programs and global initiatives such as EPI, Gavi, and IA2030 have expanded vaccine coverage and strengthened disease prevention through coordinated policies, financing, and partnerships (Lindstrand et al., 2021; Nunes et al., 2024).
Despite major achievements, immunization programs continue to face challenges including access barriers, cold-chain limitations, vaccine hesitancy, misinformation, and persistent global inequalities (Haldane et al., 2023; Santangelo et al., 2024; Dagovetz et al., 2025).
Vaccine safety monitoring systems and pharmacovigilance frameworks play a critical role in maintaining public trust by detecting, evaluating, and managing adverse events while ensuring transparency and accountability (Rudolph et al., 2022; Gee et al., 2024).
Scientific evidence consistently demonstrates that vaccines are safe, effective, and essential for preventing infectious diseases, while most concerns and myths surrounding vaccination lack credible scientific support (Geoghegan et al., 2020; Conklin et al., 2021; Löffler, 2021).
Future immunization efforts will increasingly rely on innovative vaccine technologies, personalized approaches, stronger surveillance systems, and equitable global collaboration to address emerging diseases and improve health outcomes for all populations (Jeon & Kim, 2025; Moradpour et al., 2023; Nunes et al., 2024).
Sustained political commitment, investment in healthcare infrastructure, community engagement, and international cooperation remain essential to achieving universal and equitable immunization coverage worldwide (Lindstrand et al., 2021; Jeon & Kim, 2025).

Reference

(2020). Fractional dose of intradermal compared to intramuscular and subcutaneous vaccination - A systematic review and meta-analysis. Travel Medicine and Infectious Disease, 37, 101868. https://doi.org/10.1016/j.tmaid.2020.101868
(2024a). Historical Evolution of Vaccines: Milestones in Immunization. International Journal of Veterinary Science. https://doi.org/10.47278/book.cam/2024.287
(2024b). Introduction, History, Types of Vaccines, and Physiology of Immunization. International Journal of Veterinary Science. https://doi.org/10.47278/book.cam/2024.329
(2024c). Role of Vaccination in Disease Prevention by Immunization. International Journal of Veterinary Science. https://doi.org/10.47278/book.cam/2024.246
Acosta-Coley, I., Cervantes-Ceballos, L., Tejeda-Benítez, L., Sierra-Marquez, L., Cabarcas-Montalvo, M., García-Espiñeira, M., Coronell-Rodriguez, W., & Arroyo-Salgado, B. (2022). Vaccines platforms and COVID-19: what you need to know. Tropical Diseases, Travel Medicine and Vaccines, 8. https://doi.org/10.1186/s40794-022-00176-4
Abdurrahman, Z., & Putman, D. (2023). Adverse Reactions to Vaccines. Canadian Allergy & Immunology Today. https://doi.org/10.58931/cait.2023.3255
Abukhalil, A., Shatat, S., Abushehadeh, R., Al-Shami, N., Naseef, H., & Rabba, A. (2023). Side effects of Pfizer/BioNTech (BNT162b2) COVID-19 vaccine reported by the Birzeit University community. BMC Infectious Diseases, 23. https://doi.org/10.1186/s12879-022-07974-3
Adua, A., Caraquel, K., Cruz, M., & Narvaez, R. (2022). Vaccine literacy: A concept analysis. International Journal of Mental Health Nursing, 31, 857–867. https://doi.org/10.1111/inm.12988
Adumashi, F., Obohwemu, K., Abayomi, G., Kenneth, I., Ekwuluo, C., & Ituah, F. (2026). Immunisation in the 21st Century: Foundations, Challenges, and Strategic Directions for Global Health. Advances in Social Sciences Research Journal. https://doi.org/10.14738/assrj.1302.19921
Aida, V., Pliasas, V., Neasham, P., North, J., McWhorter, K., Glover, S., & Kyriakis, C. (2021). Novel Vaccine Technologies in Veterinary Medicine: A Herald to Human Medicine Vaccines. Frontiers in Veterinary Science, 8. https://doi.org/10.3389/fvets.2021.654289
Alanazi, F., Alharbi, B., Aljuaid, T., Alammar, F., Almarzouq, Y., Albalawi, I., Almutairi, M., Alshaghroud, S., Alhaosawi, M., Albalawi, M., & Alorf, A. (2024). The impact of vaccinations on disease prevention: A comprehensive analysis of their role in enhancing global public health and reducing morbidity and mortality rates. International Journal of Health Sciences. https://doi.org/10.53730/ijhs.v8ns1.15436
Alghamdi, A., Alotaibi, M., Alqahtani, A., Aboud, A., & Abdel-Moneim, A. (2021). BNT162b2 and ChAdOx1 SARS-CoV-2 Post-vaccination Side-Effects Among Saudi Vaccinees. Frontiers in Medicine, 8. https://doi.org/10.3389/fmed.2021.760047
Altindag, O., Greve, J., & Tekin, E. (2025). Impact of Measles, Mumps, and Rubella Vaccination on Hospitalizations and Human Capital: Evidence from Copenhagen School Health Records. Vaccines, 13. https://doi.org/10.3390/vaccines13030302
Andre, F., Booy, R., Bock, H., Clemens, J., Datta, D., John, T., Lee, B., Lolekha, S., Peltola, H., Ruff, T., Santosham, M., & Schmitt, H. (2008). Vaccination greatly reduces disease, disability, death and inequity worldwide. Bulletin of the World Health Organization, 86(2), 140–146. https://doi.org/10.2471/blt.07.040089
Andrzejczak-Grządko, S., Czudy, Z., & Donderska, M. (2021). Side effects after COVID-19 vaccinations among residents of Poland. European Review for Medical and Pharmacological Sciences, 25(12), 4418–4421. https://doi.org/10.26355/eurrev_202106_26153
Arunachalam, A. (2024). Vaccines Induce Homeostatic Immunity, Generating Several Secondary Benefits. Vaccines, 12. https://doi.org/10.3390/vaccines12040396
Ashie, A., et al. (2026). Safety monitoring of the RTS,S/AS01E malaria vaccine: experiences and lessons from routine pharmacovigilance in Ghana, Kenya, and Malawi. Malaria Journal, 25. https://doi.org/10.1186/s12936-026-05889-x
Ayowole, D., Adebajo, G., Lasisi, T., & Bakai, J. (2025). Effects of climate change on vaccine storage and cold chain logistics: a qualitative study in Ogun State, Nigeria. BMJ Global Health, 10. https://doi.org/10.1136/bmjgh-2025-018990
Bangura, J., Xiao, S., Qiu, D., Ouyang, F., & Chen, L. (2020). Barriers to childhood immunization in sub-Saharan Africa: A systematic review. BMC Public Health, 20. https://doi.org/10.1186/s12889-020-09169-4
Barman, S., Soni, D., Brook, B., Nanishi, E., & Dowling, D. (2022). Precision Vaccine Development: Cues From Natural Immunity. Frontiers in Immunology, 12. https://doi.org/10.3389/fimmu.2021.662218
Baxter, D. (2007). Active and passive immunity, vaccine types, excipients and licensing. Occupational Medicine, 57(8), 552–556. https://doi.org/10.1093/occmed/kqm110
Baxter, D. (2014). Active and passive immunization for cancer. Human Vaccines & Immunotherapeutics, 10, 2123–2129. https://doi.org/10.4161/hv.29604
Bayani, F., et al. (2023). An overview of the vaccine platforms to combat COVID-19 with a focus on the subunit vaccines. Progress in Biophysics and Molecular Biology, 178, 32–49. https://doi.org/10.1016/j.pbiomolbio.2023.02.004
Betsch, C., Böhm, R., & Korn, L. (2013). Inviting free-riders or appealing to prosocial behavior? game-theoretical reflections on communicating herd immunity in vaccine advocacy. Health Psychology, 32(9), 978–985. https://doi.org/10.1037/a0031590
Betsch, C., Böhm, R., Korn, L., & Holtmann, C. (2017). On the benefits of explaining herd immunity in vaccine advocacy. Nature Human Behaviour, 1. https://doi.org/10.1038/s41562-017-0056
Bouazzaoui, A., & Abdellatif, A. (2024). Vaccine delivery systems and administration routes: Advanced biotechnological techniques to improve the immunization efficacy. Vaccine: X, 19. https://doi.org/10.1016/j.jvacx.2024.100500
Brisson, M., & Edmunds, W. (2003). Economic Evaluation of Vaccination Programs: The Impact of Herd-Immunity. Medical Decision Making, 23, 76–82. https://doi.org/10.1177/0272989x02239651
Bulut, A. (2023). Immunization and Vaccines. Experimental and Applied Medical Science. https://doi.org/10.46871/eams.1224634
Byington, C. (2017). Recommended Childhood and Adolescent Immunization Schedule—United States, 2017. Pediatrics, 139. https://doi.org/10.1542/peds.2016-4007
Calle, S. (2020). Advancements in the field of Vaccines and Immunization. Journal of Vaccines and Vaccination, 11, 1–2. https://doi.org/10.35248/2157-7560.20.11.e418
Canouï, E., & Launay, O. (2019). [History and principles of vaccination]. Revue des Maladies Respiratoires, 36(1), 74–81. https://doi.org/10.1016/j.rmr.2018.02.015
Carvalho, G., & De Oliveira Magalhães Júnior, C. (2025). Editorial: Vaccine education and promotion. Frontiers in Public Health, 13. https://doi.org/10.3389/fpubh.2025.1610968
Chaplin, D. (2006). 1. Overview of the human immune response. The Journal of Allergy and Clinical Immunology, 117(2 Suppl Mini-Primer), S430–S435. https://doi.org/10.1016/j.jaci.2005.09.034
Chevalier-Cottin, E., Ashbaugh, H., Brooke, N., Gavazzi, G., Santillana, M., Burlet, N., & Htar, T. (2020). Communicating Benefits from Vaccines Beyond Preventing Infectious Diseases. Infectious Diseases and Therapy, 9, 467–480. https://doi.org/10.1007/s40121-020-00312-7
Chuah, J., & Parasuraman, S. (2025). Overview of Types of Vaccines and Vaccination Methods. JAPA Academy Journal. https://doi.org/10.4103/japaj.japaj_19_25
Cid, R., & Bolívar, J. (2021). Platforms for Production of Protein-Based Vaccines: From Classical to Next-Generation Strategies. Biomolecules, 11. https://doi.org/10.3390/biom11081072
Clem, A. (2011). Fundamentals of Vaccine Immunology. Journal of Global Infectious Diseases, 3, 73–78. https://doi.org/10.4103/0974-777x.77299
Cole, A., Webster, P., Van Liew, D., Salas, M., Aimer, O., & Malikova, M. (2022). Safety surveillance and challenges in accelerated COVID-19 vaccine development. Therapeutic Advances in Drug Safety, 13. https://doi.org/10.1177/20420986221116452
Conis, E. (2019). Measles and the Modern History of Vaccination. Public Health Reports, 134, 118–125. https://doi.org/10.1177/0033354919826558
Cruz, E., Reyes, E., & Ruiz, Y. (2025). Vaccination: A Legacy of Success and Persistent Challenges, 50 Years Since the Launch of the Expanded Programme on Immunization. Medical Research Archives. https://doi.org/10.18103/mra.v13i3.6311
Dagovetz, M., et al. (2025). Global COVID-19 Vaccination Challenges: Inequity of Access and Vaccine Hesitancy. Journal of Medicine, Surgery, and Public Health. https://doi.org/10.1016/j.glmedi.2025.100197
Dai, X., Xiong, Y., Li, N., & Jian, C. (2019). Vaccine Types. Vaccines - the History and Future. https://doi.org/10.5772/intechopen.84626
De Los Santos, O., Perez, E., & Onate, T. (2022). Vaccines: Origin and evolution throughout history. Journal of Vaccines and Immunology. https://doi.org/10.17352/jvi.000049
Dighriri, I., et al. (2022). Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) Side Effects: A Systematic Review. Cureus, 14. https://doi.org/10.7759/cureus.23526
Diseases, C. (2023). Recommended Childhood and Adolescent Immunization Schedule: United States, 2024. Pediatrics. https://doi.org/10.1542/peds.2023-065044
Divangahi, M., et al. (2020). Trained immunity, tolerance, priming and differentiation: distinct immunological processes. Nature Immunology, 22, 2–6. https://doi.org/10.1038/s41590-020-00845-6
Doherty, M., Buchy, P., Standaert, B., Giaquinto, C., & Prado-Cohrs, D. (2016). Vaccine impact: Benefits for human health. Vaccine, 34(52), 6707–6714. https://doi.org/10.1016/j.vaccine.2016.10.025
Domachowske, J. (2020a). Active Immunization. Vaccines. https://doi.org/10.1007/978-3-030-58414-6_3
Domachowske, J. (2020b). Passive Immunization. Vaccines. https://doi.org/10.1007/978-3-030-58414-6_2
El-Masry, E. (2021). Immunization against severe acute respiratory syndrome Coronavirus 2: an overview. African Health Sciences, 21, 1574–1583. https://doi.org/10.4314/ahs.v21i4.11
Fahrni, M., et al. (2022). Management of COVID-19 vaccines cold chain logistics: a scoping review. Journal of Pharmaceutical Policy and Practice, 15. https://doi.org/10.1186/s40545-022-00411-5
Fatinah, Y., Qolbina, M., Alfaqeeh, M., Insani, W., Sinuraya, R., Hamad, A., & Suwantika, A. (2026). Childhood immunization barriers and interventions in low- and middle-income countries: A scoping review of access, delivery systems, and health literacy. Human Vaccines & Immunotherapeutics, 22. https://doi.org/10.1080/21645515.2026.2651508
Fousseni, S., et al. (2025). Navigating the Road to Immunization Equity: Systematic Review of Challenges in Introducing New Vaccines into Sub-Saharan Africa’s Health Systems. Vaccines, 13. https://doi.org/10.3390/vaccines13030269
Francis, M. (2017). Recent Advances in Vaccine Technologies. The Veterinary Clinics of North America. Small Animal Practice, 48, 231–241. https://doi.org/10.1016/j.cvsm.2017.10.002
Gaievskyi, S., et al. (2026). Assessing vaccine cold chain storage and transport in Ukraine: a cross-sectional study. BMC Health Services Research, 26. https://doi.org/10.1186/s12913-026-14332-5
García, F., et al. (2023). Immunisation schedule of the Spanish Association of Paediatrics: 2023 Recommendations. Anales de Pediatría, 98(1), 58.e1-58.e10. https://doi.org/10.1016/j.anpede.2022.11.002
Garros, M., Rolando, A., Ponce, J., Ovejero, S., & Toranzos, H. (2023). Análisis sistémico del programa de vacunación en Argentina. Health Leadership and Quality of Life. https://doi.org/10.56294/hl202332
Geckin, B., Föhse, F., Domínguez-Andrés, J., & Netea, M. (2022). Trained immunity: implications for vaccination. Current Opinion in Immunology, 77, 102190. https://doi.org/10.1016/j.coi.2022.102190
Gee, J., et al. (2024). Overview of U.S. COVID-19 vaccine safety surveillance systems. Vaccine. https://doi.org/10.1016/j.vaccine.2024.02.065
Ghattas, M., Dwivedi, G., Lavertu, M., & Alameh, M. (2021). Vaccine Technologies and Platforms for Infectious Diseases: Current Progress, Challenges, and Opportunities. Vaccines, 9. https://doi.org/10.3390/vaccines9121490
Ghosh, D., Jiang, W., Mukhopadhyay, D., & Mellins, E. (2021). New insights into B cells as antigen presenting cells. Current Opinion in Immunology, 70, 129–137. https://doi.org/10.1016/j.coi.2021.06.003
Gupta, S., & Pellett, S. (2023). Recent Developments in Vaccine Design: From Live Vaccines to Recombinant Toxin Vaccines. Toxins, 15. https://doi.org/10.3390/toxins15090563
Hagos, A., Sahile, Z., Ahmed, W., & Phanouvong, S. (2024). Leveraging COVID-19 Vaccine Safety Monitoring in Ethiopia and Pakistan to Enhance System-Wide Safety Surveillance. Global Health: Science and Practice, 12. https://doi.org/10.9745/ghsp-d-23-00161
Haldane, V., Ariyarajah, A., Berry, I., Loutet, M., Salamanca-Buentello, F., & Upshur, R. (2023). Global inequity creates local insufficiency: A qualitative study of COVID-19 vaccine implementation challenges in low-and-middle-income countries. PLOS ONE, 18. https://doi.org/10.1371/journal.pone.0281358
Hanson, C., George, A., Sawadogo, A., & Schreiber, B. (2017). Is freezing in the vaccine cold chain an ongoing issue? A literature review. Vaccine, 35(17), 2127–2133. https://doi.org/10.1016/j.vaccine.2016.09.070
Hillion, S., et al. (2019). The Innate Part of the Adaptive Immune System. Clinical Reviews in Allergy & Immunology, 58, 151–154. https://doi.org/10.1007/s12016-019-08740-1
Hussain, S. (2019). Immunization and Vaccination. Psychiatry of Pandemics, 153–177. https://doi.org/10.1007/978-3-030-15346-5_13
Issa, A., Wodi, A., Moser, C., & Cineas, S. (2025). Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger — United States, 2025. Morbidity and Mortality Weekly Report, 74, 26–29. https://doi.org/10.15585/mmwr.mm7402a2
James, E. (2021). Disrupting vaccine logistics. International Health, 13, 211–214. https://doi.org/10.1093/inthealth/ihab010
John, T. (2018). World Immunization Week 2018: What lessons for India?. The Indian Journal of Medical Research, 147, 330–333. https://doi.org/10.4103/ijmr.ijmr_469_18
Jong, E. (2021). Immunizations. Schlossberg's Clinical Infectious Disease. https://doi.org/10.1017/cbo9780511722240.114
Kahn, A., et al. (2024). Stakeholder Consultation Workshop on the Perceived Value of Thermostable Vaccines to Relieve Program Barriers: A Case Study from Côte d’Ivoire. Vaccines, 12. https://doi.org/10.3390/vaccines12121414
Kalenik, B., Sawicka, R., Góra-Sochacka, A., & Sirko, A. (2014). Influenza prevention and treatment by passive immunization. Acta Biochimica Polonica, 61(3), 573–587. https://doi.org/10.18388/abp.2014_1879
Kartoglu, U., & Ames, H. (2022). Ensuring quality and integrity of vaccines throughout the cold chain: the role of temperature monitoring. Expert Review of Vaccines, 21, 799–810. https://doi.org/10.1080/14760584.2022.2061462
Kennedy, M. (2020). Role of Immunization. 1565–1570. https://doi.org/10.1002/9781119501237.ch176
Khairi, L., Fahrni, M., & Lazzarino, A. (2022). The Race for Global Equitable Access to COVID-19 Vaccines. Vaccines, 10. https://doi.org/10.3390/vaccines10081306
Khebade, V., Mali, A., & Sanap, G. (2024). Immunization. International Journal of Advanced Research in Science, Communication and Technology. https://doi.org/10.48175/ijarsct-15072
Kholina, K., Harmon, S., & Graham, J. (2022). An equitable vaccine delivery system: Lessons from the COVID-19 vaccine rollout in Canada. PLOS ONE, 17. https://doi.org/10.1371/journal.pone.0279929
Kiboneka, A. (2021a). Basic concepts in clinical immunology: A review. World Journal of Advanced Research and Reviews. https://doi.org/10.30574/wjarr.2021.12.3.0745
Kiboneka, A. (2021b). Understanding childhood immunizations, their serological interpretation and vaccines - A review article. World Journal of Advanced Research and Reviews. https://doi.org/10.30574/wjarr.2021.10.3.0275
Kiboneka, A., & Mwesigwa, R. (2023). A primer on immune responses and mechanisms. World Journal of Advanced Research and Reviews. https://doi.org/10.30574/wjarr.2023.18.2.0814
Lakshmanan, M., & Karunakaran, U. (2020). Polio vaccination coverage among children aged 12-23 months in a health block in North Kerala. International Journal of Community Medicine and Public Health, 7, 2291. https://doi.org/10.18203/2394-6040.ijcmph20202488
Lasocka, J., Bielawski, A., & Lachert, E. (2021). Passive immunization in the combat against infectious diseases (COVID-19 included). Journal of Transfusion Medicine. https://doi.org/10.5603/jtm.2021.0004
Li, Y., Tenchov, R., Smoot, J., Liu, C., Watkins, S., & Zhou, Q. (2021). A Comprehensive Review of the Global Efforts on COVID-19 Vaccine Development. ACS Central Science, 7, 512–533. https://doi.org/10.1021/acscentsci.1c00120
Li, M., et al. (2022). COVID-19 vaccine development: milestones, lessons and prospects. Signal Transduction and Targeted Therapy, 7. https://doi.org/10.1038/s41392-022-00996-y
Liu, Z., Dai, H., Cui, X., Liu, Y., & Dong, Z. (2025). Importance of B cells (Review). International Journal of Molecular Medicine, 57(1). https://doi.org/10.3892/ijmm.2025.5673
Lotfi, H., Mazar, M., Ei, N., Fahim, M., & Yazdi, N. (2023). Vaccination is the most effective and best way to avoid the disease of COVID‐19. Immunity, Inflammation and Disease, 11. https://doi.org/10.1002/iid3.946
Luyten, J., & Beutels, P. (2016). The Social Value Of Vaccination Programs: Beyond Cost-Effectiveness. Health Affairs, 35(2), 212–218. https://doi.org/10.1377/hlthaff.2015.1088
Marcotte, H., & Hammarström, L. (2015). Passive Immunization. Mucosal Immunology, 1403–1434. https://doi.org/10.1016/b978-0-12-415847-4.00071-9
Marineci, C., & Chiriţă, C. (2018). Agenţi de imunizare. Vaccinuri.
Marshall, J., Warrington, R., Watson, W., & Kim, H. (2018). An introduction to immunology and immunopathology. Allergy, Asthma, and Clinical Immunology, 14. https://doi.org/10.1186/s13223-018-0278-1
Marshall, J., Upton, J., Vliagoftis, H., Hildebrand, K., Byrne, A., & Watson, W. (2024). Introduction to immunology and immune disorders. Allergy, Asthma, and Clinical Immunology, 20. https://doi.org/10.1186/s13223-024-00932-5
Martin, J., & Graham, B. (2016). Immunization Against Viral Diseases. 333–349. https://doi.org/10.1128/9781555815981.ch15
Medzhitov, R., & Janeway, C. (1997). Innate immunity: impact on the adaptive immune response. Current Opinion in Immunology, 9(1), 4–9. https://doi.org/10.1016/s0952-7915(97)80152-5
Mohebbi, A., et al. (2023). Adverse Effects Reported and Insights Following Sinopharm COVID-19 Vaccination. Current Microbiology, 80. https://doi.org/10.1007/s00284-023-03432-8
Montero, D., et al. (2024). Two centuries of vaccination: historical and conceptual approach and future perspectives. Frontiers in Public Health, 11. https://doi.org/10.3389/fpubh.2023.1326154
Moore, R. (2019). Thanks …. 403–403. https://doi.org/10.2307/j.ctvmd85t4.4
Motamedi, H., et al. (2021). An update review of globally reported SARS-CoV-2 vaccines in preclinical and clinical stages. International Immunopharmacology, 96, 107763. https://doi.org/10.1016/j.intimp.2021.107763
Mu, J., et al. (2022). Comparative study of subcutaneous, intramuscular, and oral administration of bovine pathogenic Escherichia coli bacterial ghost vaccine in mice. Frontiers in Immunology, 13. https://doi.org/10.3389/fimmu.2022.1008131
Musuka, G., et al. (2025). Immunization Coverage, Equity, and Access for Children with Disabilities: A Scoping Review of Challenges, Strategies, and Lessons Learned to Reduce the Number of Zero-Dose Children. Vaccines, 13. https://doi.org/10.3390/vaccines13040377
Nambasa, V., et al. (2025). Pharmacovigilance for Vaccines Used in Pregnancy: A Gap Analysis From Uganda. The Pediatric Infectious Disease Journal, 44, S123–S129. https://doi.org/10.1097/inf.0000000000004705
Nandi, A., & Shet, A. (2020). Why vaccines matter: understanding the broader health, economic, and child development benefits of routine vaccination. Human Vaccines & Immunotherapeutics, 16, 1900–1904. https://doi.org/10.1080/21645515.2019.1708669
Nuwarda, R., Ramzan, I., Weekes, L., & Kayser, V. (2022). Vaccine Hesitancy: Contemporary Issues and Historical Background. Vaccines, 10. https://doi.org/10.3390/vaccines10101595
O’Leary, S. (2026). Recommended Childhood and Adolescent Immunization Schedule: United States, 2026: Policy Statement. Pediatrics. https://doi.org/10.1542/peds.2025-075754
Ochando, J., Mulder, W., Madsen, J., Netea, M., & Duivenvoorden, R. (2022). Trained immunity — basic concepts and contributions to immunopathology. Nature Reviews. Nephrology, 19, 23–37. https://doi.org/10.1038/s41581-022-00633-5
Ols, S., et al. (2020). Route of Vaccine Administration Alters Antigen Trafficking but Not Innate or Adaptive Immunity. Cell Reports, 30(12), 3964–3971.e7. https://doi.org/10.1016/j.celrep.2020.02.111
Oosterhuis, I., Scholl, J., Van Puijenbroek, E., Kant, A., & Van Hunsel, F. (2022). Optimizing Safety Surveillance for COVID-19 Vaccines at the National Pharmacovigilance Centre Lareb: One Year of COVID-19 Vaccine Experience. Drug Safety, 46, 65–75. https://doi.org/10.1007/s40264-022-01253-5
Orenstein, W., & Ahmed, R. (2017). Simply put: Vaccination saves lives. Proceedings of the National Academy of Sciences, 114, 4031–4033. https://doi.org/10.1073/pnas.1704507114
Padilla-Flores, T., Sampieri, A., & Vaca, L. (2024). Incidence and management of the main serious adverse events reported after COVID‐19 vaccination. Pharmacology Research & Perspectives, 12. https://doi.org/10.1002/prp2.1224
Pambudi, N., Sarifudin, A., Gandidi, I., & Romadhon, R. (2021). Vaccine cold chain management and cold storage technology to address the challenges of vaccination programs. Energy Reports, 8, 955–972. https://doi.org/10.1016/j.egyr.2021.12.039
Park, J., & Lee, H. (2021). Delivery Routes for COVID-19 Vaccines. Vaccines, 9. https://doi.org/10.3390/vaccines9050524
Parkin, J., & Cohen, B. (2001). An overview of the immune system. Lancet, 357(9270), 1777–1789. https://doi.org/10.1016/s0140-6736(00)04904-7
Pathan, A., Anjum, R., & Barkat, A. (2025). Concept of Vaccination and Immunization in Islam and Contemporary Law. The Critical Review of Social Sciences Studies. https://doi.org/10.59075/ytpwdx74
Pezzotti, P., et al. (2018). The impact of immunization programs on 10 vaccine preventable diseases in Italy: 1900-2015. Vaccine, 36(11), 1435–1443. https://doi.org/10.1016/j.vaccine.2018.01.065
Phillips, A., Carlson, S., Danchin, M., Beard, F., & Macartney, K. (2021). From program suspension to the pandemic: A qualitative examination of Australia’s vaccine pharmacovigilance system over 10 years. Vaccine, 39, 5968–5981. https://doi.org/10.1016/j.vaccine.2021.07.059
Piot, P., Larson, H., O’Brien, K., N’kengasong, J., Ng, E., Sow, S., & Kampmann, B. (2019). Immunization: vital progress, unfinished agenda. Nature, 575, 119–129. https://doi.org/10.1038/s41586-019-1656-7
Pishesha, N., Harmand, T., & Ploegh, H. (2022). A guide to antigen processing and presentation. Nature Reviews Immunology, 22, 751–764. https://doi.org/10.1038/s41577-022-00707-2
Pocevski, B., Pocevski, P., & Pocevski, M. (2024). Vaccination against influenza virus: Immunization as the basic of public health. Proceedings of the International Congress Public Health - Achievements and Challenges - zbornik radova. https://doi.org/10.5937/batutphco24135p
Pollard, A., & Bijker, E. (2020). A guide to vaccinology: from basic principles to new developments. Nature Reviews Immunology, 21, 83–100. https://doi.org/10.1038/s41577-020-00479-7
Pradeu, T., Thomma, B., Girardin, S., & Lemaitre, B. (2024). The conceptual foundations of innate immunity: Taking stock 30 years later. Immunity, 57(4), 613–631. https://doi.org/10.1016/j.immuni.2024.03.007
Pulendran, B., & Ahmed, R. (2006). Translating innate immunity into immunological memory: implications for vaccine development. Cell, 124(4), 849–863. https://doi.org/10.1016/j.cell.2006.02.019
Rai, C., Kuo, T., & Chen, Y. (2024). Novel Administration Routes, Delivery Vectors, and Application of Vaccines Based on Biotechnologies: A Review. Vaccines, 12. https://doi.org/10.3390/vaccines12091002
Rankin, L., & Artis, D. (2018). Beyond Host Defense: Emerging Functions of the Immune System in Regulating Complex Tissue Physiology. Cell, 173(3), 554–567. https://doi.org/10.1016/j.cell.2018.03.013
Rastogi, I., Jeon, D., Moseman, J., Muralidhar, A., Potluri, H., & McNeel, D. (2022). Role of B cells as antigen presenting cells. Frontiers in Immunology, 13. https://doi.org/10.3390/fimmu.2022.954936
Robinson, C., Romero, J., & Kempe, A. (2017a). Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger — United States, 2017. American Journal of Transplantation, 17, 1136–1138. https://doi.org/10.1111/ajt.14245
Robinson, C., Romero, J., Kempe, A., & Pellegrini, C. (2017b). Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger — United States, 2017. Morbidity and Mortality Weekly Report, 66, 134–135. https://doi.org/10.1111/ajt.14245
Robinson, C., Romero, J., Kempe, A., Pellegrini, C., & Szilagyi, P. (2018). Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger — United States, 2018. Morbidity and Mortality Weekly Report, 67, 156–157. https://doi.org/10.15585/mmwr.mm6705e2
Robinson, C., Bernstein, H., Poehling, K., Romero, J., & Szilagyi, P. (2020). Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger — United States, 2020. Morbidity and Mortality Weekly Report, 69, 130–132. https://doi.org/10.15585/mmwr.mm6905a3
Rosenbaum, P., et al. (2020). Vaccine Inoculation Route Modulates Early Immunity and Consequently Antigen-Specific Immune Response. Frontiers in Immunology, 12. https://doi.org/10.3389/fimmu.2021.645210
Rudolph, A., et al. (2022). Global safety monitoring of COVID-19 vaccines: how pharmacovigilance rose to the challenge. Therapeutic Advances in Drug Safety, 13. https://doi.org/10.1177/20420986221118972
Sadeeqa, S. (2018). Public Perception and Compliance to Immunization. https://doi.org/10.23880/vvoa-16000116
Saeed, B., Al-Shahrabi, R., Alhaj, S., Alkokhardi, Z., & Adrees, A. (2021). Side effects and perceptions following Sinopharm COVID-19 vaccination. International Journal of Infectious Diseases, 111, 219–226. https://doi.org/10.1016/j.ijid.2021.08.013
Sáfadi, M. (2021). Vaccine Types. VacciTUTOR. https://doi.org/10.33442/vt202106
Saiyad, S., Bhanderi, B., & Koringa, P. (2024). Recent advances in veterinary vaccines. International Journal of Advanced Biochemistry Research. https://doi.org/10.33545/26174693.2024.v8.i4sc.981
Salmon, D., Chen, R., Black, S., & Sharfstein, J. (2024). Lessons learned from COVID-19, H1N1, and routine vaccine pharmacovigilance in the United States: a path to a more robust vaccine safety program. Expert Opinion on Drug Safety, 23, 161–175. https://doi.org/10.1080/14740338.2024.2305707
Santangelo, O., Provenzano, S., Di Martino, G., & Ferrara, P. (2024). COVID-19 Vaccination and Public Health: Addressing Global, Regional, and Within-Country Inequalities. Vaccines, 12. https://doi.org/10.3390/vaccines12080885
Schnyder, J., et al. (2021). Comparison of equivalent fractional vaccine doses delivered by intradermal and intramuscular or subcutaneous routes: A systematic review. Travel Medicine and Infectious Disease, 102007. https://doi.org/10.1016/j.tmaid.2021.102007
Sevilla, J. (2023). Immunization, not vaccination: monoclonal antibodies for infant RSV prevention and the US vaccines for children program. Journal of Medical Economics, 26, 991–997. https://doi.org/10.1080/13696998.2023.2242169
Shattock, A., et al. (2024). Contribution of vaccination to improved survival and health: modelling 50 years of the Expanded Programme on Immunization. Lancet, 403, 2307–2316. https://doi.org/10.1016/s0140-6736(24)00850-x
Shimp, L., Ghosh, R., & Elkes, K. (2023). Addressing Immunization Inequity—What Have the International Community and India Learned over 35 Years?. Vaccines, 11. https://doi.org/10.3390/vaccines11040790
Shukla, V., & Shah, R. (2018). Vaccinations in Primary Care. The Indian Journal of Pediatrics, 85, 1118–1127. https://doi.org/10.1007/s12098-017-2555-2
Simoens, S., et al. (2024). The broader benefits of vaccines: methodologies for inclusion in economic evaluation. Expert Review of Vaccines, 23, 779–788. https://doi.org/10.1080/14760584.2024.2387599
Sinnei, D., Karimi, P., Maru, S., Karengera, S., & Bizimana, T. (2023). Evaluation of vaccine storage and distribution practices in rural healthcare facilities in Kenya. Journal of Pharmaceutical Policy and Practice, 16. https://doi.org/10.1186/s40545-023-00535-2
Smith, N., Rise, M., & Christian, S. (2019). A Comparison of the Innate and Adaptive Immune Systems in Cartilaginous Fish, Ray-Finned Fish, and Lobe-Finned Fish. Frontiers in Immunology, 10. https://doi.org/10.3389/fimmu.2019.02292
Stone, C., Rukasin, C., Beachkofsky, T., & Phillips, E. (2019). Immune‐mediated adverse reactions to vaccines. British Journal of Clinical Pharmacology, 85, 2694–2706. https://doi.org/10.1111/bcp.14112
Strully, K., Harrison, T., Pardo, T., & Carleo-Evangelist, J. (2021). Strategies to Address COVID-19 Vaccine Hesitancy and Mitigate Health Disparities in Minority Populations. Frontiers in Public Health, 9. https://doi.org/10.3389/fpubh.2021.645268
Sun, L., Wang, X., Saredy, J., Yuan, Z., Yang, X., & Wang, H. (2020). Innate-adaptive immunity interplay and redox regulation in immune response. Redox Biology, 37. https://doi.org/10.1016/j.redox.2020.101759
Sun, J., et al. (2022). Dataset of ultralow temperature refrigeration for COVID 19 vaccine distribution solution. Scientific Data, 9. https://doi.org/10.1038/s41597-022-01167-y
Talbot, A., De Koning-Ward, T., & Layton, D. (2024). Left out in the cold - inequity in infectious disease control due to cold chain disparity. Vaccine, 45, 126648. https://doi.org/10.1016/j.vaccine.2024.126648
Tang, J., Amin, M., & Campian, J. (2025). Past, Present, and Future of Viral Vector Vaccine Platforms: A Comprehensive Review. Vaccines, 13. https://doi.org/10.3390/vaccines13050524
Tinessia, A., et al. (2025). Systematic review of pro-equity strategies to improve vaccination among priority populations. Vaccine, 64, 127694. https://doi.org/10.1101/2025.06.03.25328765
Tong, C., (2019). Different Types of Vaccines. Tutorial Topics in Infection for the Combined Infection Training Programme. https://doi.org/10.1093/oso/9780198801740.003.0061
Touray, M., & Touray, A. (2021). Immunization and Vaccines. Sustainable Development Goals Series. https://doi.org/10.1007/978-3-030-71032-3_23
Toxvaerd, F., & Rowthorn, R. (2022). On the management of population immunity. Journal of Economic Theory, 204, 105501. https://doi.org/10.1016/j.jet.2022.105501
Travieso, T., Li, J., Mahesh, S., Mello, J., & Blasi, M. (2022). The use of viral vectors in vaccine development. NPJ Vaccines, 7. https://doi.org/10.1038/s41541-022-00503-y
Upasani, V., Rodenhuis-Zybert, I., & Cantaert, T. (2021). Antibody-independent functions of B cells during viral infections. PLoS Pathogens, 17. https://doi.org/10.1371/journal.ppat.1009708
Vetter, V., Denizer, G., Friedland, L., Krishnan, J., & Shapiro, M. (2018). Understanding modern-day vaccines: what you need to know. Annals of Medicine, 50, 110–120. https://doi.org/10.1080/07853890.2017.1407035
Vuscan, P., Kischkel, B., Joosten, L., & Netea, M. (2024). Trained immunity: General and emerging concepts. Immunological Reviews, 323, 164–185. https://doi.org/10.1111/imr.13326
Waldman, R., & Ganguly, R. (1984). Immunization against viral infections. Successful, ongoing mode of defense. Postgraduate Medicine, 75(1), 170–176, 181–187. https://doi.org/10.1080/00325481.1984.11698565
Wallace, A., et al. (2022). Leaving no one behind: Defining and implementing an integrated life course approach to vaccination across the next decade as part of the immunization Agenda 2030. Vaccine. https://doi.org/10.1016/j.vaccine.2022.11.039
Wang, R., et al. (2024). The interaction of innate immune and adaptive immune system. MedComm, 5. https://doi.org/10.1002/mco2.714
Wang, Y., et al. (2025). Evaluation and optimization of mumps-containing vaccination strategies: a study based on an individual-based stochastic model. eClinicalMedicine, 90. https://doi.org/10.1016/j.eclinm.2025.103620
Warrington, R., Watson, W., Kim, H., & Antonetti, F. (2011). An introduction to immunology and immunopathology. Allergy, Asthma, and Clinical Immunology, 7, S1. https://doi.org/10.1186/1710-1492-7-s1-s1
Wasiullah, W., Yadav, Y., Yadav, G., Vishwakarma, M., & Yadav, R. (2025). Enhancing Vaccine Safety: The Role of Pharmacovigilance in Public Health. International Journal of Pharmaceutical Research and Applications. https://doi.org/10.35629/4494-100224132417
Wodi, A., Murthy, N., McNally, V., Cineas, S., & Ault, K. (2023). Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger — United States, 2023. Morbidity and Mortality Weekly Report, 72, 137–140. https://doi.org/10.15585/mmwr.mm7206a1
Wodi, A., Murthy, N., McNally, V., Daley, M., & Cineas, S. (2024). Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger — United States, 2024. Morbidity and Mortality Weekly Report, 73, 6–10. https://doi.org/10.15585/mmwr.mm7301a2
Yang, D., Tian, J., Shen, C., & Li, Q. (2024). An overview and single-arm meta-analysis of immune-mediated adverse events following COVID-19 vaccination. Frontiers in Pharmacology, 15. https://doi.org/10.3389/fphar.2024.1308768
Yang, X., Zhang, L., Staykov, K., Wu, Z., & Jaklenec, A. (2025). Transforming drug and vaccine delivery for equitable access in global health. Biochemical and Biophysical Research Communications, 779, 152415. https://doi.org/10.1016/j.bbrc.2025.152415
Zhao, H., et al. (2023). Immune Response of Inactivated Rabies Vaccine Inoculated via Intraperitoneal, Intramuscular, Subcutaneous and Needle-Free Injection Technology-Based Intradermal Routes in Mice. International Journal of Molecular Sciences, 24. https://doi.org/10.3390/ijms241713587
(2024). Recommended Childhood and Adolescent Immunization Schedule: United States, 2025: Policy Statement. Pediatrics. https://doi.org/10.1542/peds.2024-069987
S., A, A., Thotamsetty, L., Ravilla, S., Nadikudi, N., & Doddayya, H. (2017). Assessment of knowledge, attitude and perception among mothers towards immunization in a tertiary care teaching hospital. International Journal of Community Medicine and Public Health, 4, 3429. https://doi.org/10.18203/2394-6040.ijcmph20173857